My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 221

    1.

    Combined use of rosiglitazone and fenofibrate in patients with type 2 diabetes: prevention of fluid retention.

    Boden G, Homko C, Mozzoli M, Zhang M, Kresge K, Cheung P.

    Diabetes. 2007 Jan;56(1):248-55.PMID: 17192489 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients.

    Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, DeFronzo RA.

    J Clin Endocrinol Metab. 2004 Sep;89(9):4312-9.PMID: 15356026 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.

    Maggs DG, Buchanan TA, Burant CF, Cline G, Gumbiner B, Hsueh WA, Inzucchi S, Kelley D, Nolan J, Olefsky JM, Polonsky KS, Silver D, Valiquett TR, Shulman GI.

    Ann Intern Med. 1998 Feb 1;128(3):176-85.PMID: 9454525 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.

    Miyazaki Y, DeFronzo RA.

    Diabetes Obes Metab. 2008 Dec;10(12):1204-11. Epub 2008 May 12.PMID: 18476983 [PubMed - indexed for MEDLINE]Related articles

    5.

    Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients.

    Miyazaki Y, He H, Mandarino LJ, DeFronzo RA.

    Diabetes. 2003 Aug;52(8):1943-50.PMID: 12882909 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients.

    Bajaj M, Suraamornkul S, Piper P, Hardies LJ, Glass L, Cersosimo E, Pratipanawatr T, Miyazaki Y, DeFronzo RA.

    J Clin Endocrinol Metab. 2004 Jan;89(1):200-6.PMID: 14715850 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Results of a placebo-controlled study of the metabolic effects of the addition of metformin to sulfonylurea-treated patients. Evidence for a central role of adipose tissue.

    Abbasi F, Kamath V, Rizvi AA, Carantoni M, Chen YD, Reaven GM.

    Diabetes Care. 1997 Dec;20(12):1863-9.PMID: 9405908 [PubMed - indexed for MEDLINE]Related articles

    8.

    Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: a prospective, randomized crossover study.

    Chappuis B, Braun M, Stettler C, Allemann S, Diem P, Lumb PJ, Wierzbicki AS, James R, Christ ER.

    Diabetes Metab Res Rev. 2007 Jul;23(5):392-9.PMID: 17211855 [PubMed - indexed for MEDLINE]Related articles

    9.

    Chronic treatment with pioglitazone does not protect obese patients with diabetes mellitus type II from free fatty acid-induced insulin resistance.

    Serlie MJ, Allick G, Groener JE, Ackermans MT, Heijligenberg R, Voermans BC, Aerts JM, Meijer AJ, Sauerwein HP.

    J Clin Endocrinol Metab. 2007 Jan;92(1):166-71. Epub 2006 Oct 24.PMID: 17062758 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Effects of metformin and rosiglitazone monotherapy on insulin-mediated hepatic glucose uptake and their relation to visceral fat in type 2 diabetes.

    Iozzo P, Hallsten K, Oikonen V, Virtanen KA, Parkkola R, Kemppainen J, Solin O, Lonnqvist F, Ferrannini E, Knuuti J, Nuutila P.

    Diabetes Care. 2003 Jul;26(7):2069-74.PMID: 12832315 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Discrepancies in the regulation of plasma adiponectin and TNF-alpha levels and adipose tissue gene expression in obese African Americans with glucose intolerance: a pilot study using rosiglitazone.

    Osei K, Gaillard T, Cook C, Kaplow J, Bullock M, Schuster D.

    Ethn Dis. 2005 Autumn;15(4):641-8.PMID: 16259488 [PubMed - indexed for MEDLINE]Related articles

    12.

    Thiazolidinediones increase hepatic insulin extraction in African Americans with impaired glucose tolerance and type 2 diabetes mellitus. A pilot study of rosiglitazone.

    Osei K, Gaillard T, Schuster D.

    Metabolism. 2007 Jan;56(1):24-9.PMID: 17161222 [PubMed - indexed for MEDLINE]Related articles

    13.

    Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type 2 diabetes.

    Bajaj M, Suraamornkul S, Kashyap S, Cusi K, Mandarino L, DeFronzo RA.

    J Clin Endocrinol Metab. 2004 Sep;89(9):4649-55.PMID: 15356076 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Rosiglitazone improves postprandial triglyceride and free fatty acid metabolism in type 2 diabetes.

    van Wijk JP, de Koning EJ, Castro Cabezas M, Rabelink TJ.

    Diabetes Care. 2005 Apr;28(4):844-9.PMID: 15793183 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients.

    Bajaj M, Suraamornkul S, Romanelli A, Cline GW, Mandarino LJ, Shulman GI, DeFronzo RA.

    Diabetes. 2005 Nov;54(11):3148-53.PMID: 16249438 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Rosiglitazone improves myocardial glucose uptake in patients with type 2 diabetes and coronary artery disease: a 16-week randomized, double-blind, placebo-controlled study.

    Lautamäki R, Airaksinen KE, Seppänen M, Toikka J, Luotolahti M, Ball E, Borra R, Härkönen R, Iozzo P, Stewart M, Knuuti J, Nuutila P.

    Diabetes. 2005 Sep;54(9):2787-94.PMID: 16123370 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects.

    Frias JP, Yu JG, Kruszynska YT, Olefsky JM.

    Diabetes Care. 2000 Jan;23(1):64-9.PMID: 10857970 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Further evidence for a central role of adipose tissue in the antihyperglycemic effect of metformin.

    Abbasi F, Carantoni M, Chen YD, Reaven GM.

    Diabetes Care. 1998 Aug;21(8):1301-5.PMID: 9702437 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients.

    Miyazaki Y, Glass L, Triplitt C, Matsuda M, Cusi K, Mahankali A, Mahankali S, Mandarino LJ, DeFronzo RA.

    Diabetologia. 2001 Dec;44(12):2210-9.PMID: 11793023 [PubMed - indexed for MEDLINE]Related articles

    20.

    Effect of thiazolidinediones on glucose and fatty acid metabolism in patients with type 2 diabetes.

    Boden G, Cheung P, Mozzoli M, Fried SK.

    Metabolism. 2003 Jun;52(6):753-9.PMID: 12800103 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity